HK Stock Market Move | GIANT BIOGENE (02367) fell over 6% again as the company actively adjusts its channel structure, and its performance in the first half of the year has come under pressure.

GIANT BIOGENE (02367) fell over 6% again, and as of the time of writing, it has dropped by 5.95%, trading at HKD 27.84, with a transaction volume of HKD 118 million. In terms of news, GIANT BIOGENE announced its performance, reporting revenue of approximately RMB 2.918 billion for the first half of the year, a year-on-year decrease of 6.3%; the net profit attributable to shareholders was RMB 940 million, a year-on-year decline of 20.5%. The performance pressure is mainly due to the companys proactive adjustment of its channel structure, a decrease in the proportion of influencer live streaming, and an increase in brand and new product promotion. However, the company remains focused on long-term operational quality, consolidating its channel and product competitiveness. GF SEC pointed out that with a low base and the ramp-up of new products, they are optimistic about growth recovery in H2 26. The companys brand momentum is stabilizing and rebounding, with strong performances from its two main brands during the 618 promotional event. Looking ahead, the skincare segment is expected to benefit from the ramp-up of new products like the Super Transparent Stick and adjustments to the channel structure. Meanwhile, the medical beauty segment is anticipated to see a commercial rollout of the three types of collagen devices, which may open up a second growth curve and drive the companys performance back onto a growth trajectory.